Hepatic histopathology (Fig.4-A, B) showed that both semaglutide and tirzepatide significantly reduced the non-alcoholic fatty liver disease activity score (NAS) by decreasing steatosis and cell ballooning, compared to the non-restricted diet model group
"The degree of mean weight reduction seen in SURMOUNT-2 has not been previously achieved in phase 3 trials for obesity or overweight and type 2 diabetes." Participants taking tirzepatide achieved average weight reductions of 13.4% (29.8 lb.) on the lower dose of 10 mg and 15.7% (34.4 lb.) on the higher dose of 15 mg, compared to a placebo group
In fact, in physiological conditions, AGEs are formed very slowly while, in particular conditions like hyperglycemia, insulin resistance, obesity, aging, oxidative stress and hypoxia, their formation process is accelerated [33]
For anaemias resulting from Vitamin B12 deficiencies in horses, cattle, dogs and cats